OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 803 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR Long-Term Follow-Up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options... October 14, 2022 A Remarkable Group of Patients with Haematological Disorders with No or... December 15, 2021 Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... October 11, 2024 Improving Cancer Immunotherapy: Overcoming the Problem of ‘Exhausted’ T Cells July 18, 2019 Load more HOT NEWS Mom Fighting Breast Cancer Says Her Haunted House Is Something To... A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... 37-Year-Old Mom Breaks American Marathon Record ΚΑΡΚΙΝΟΣ ΕΝΔΟΜΗΤΡΙΟΥ
